Cargando…

Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study

INTRODUCTION: The Coronavirus disease 2019 (COVID-19) pandemic and the resulting social distancing, determined a reduction in access to care and limitations of individual freedom, with a consequent strong impact on quality of life (QoL), anxiety levels and medical management of onco-hematological pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavalca, Fabrizio, Renso, Rossella, Zambrotta, Giovanni Paolo Maria, Gambacorti-Passerini, Carlo, Elli, Elena Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082139/ https://www.ncbi.nlm.nih.gov/pubmed/33937081 http://dx.doi.org/10.3389/fonc.2021.668261

Ejemplares similares

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

PB2182: NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AT DIAGNOSIS IN ESSENTIAL THROMBOCYTEMIA (ET): A NEW PREDICTOR OF THROMBOTIC EVENTS
por: Ripamonti, Alessia, et al.
Publicado: (2023)

Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization
por: Civettini, Ivan, et al.
Publicado: (2023)

PB1976: SINGLE CENTER STUDY ON SARS-COV-2 INFECTION IN PATIENTS AFFECTED BY CML: VACCINATION STATUS AND BOSUTINIB THERAPY AS POSSIBLE PROTECTIVE FACTORS FOR HOSPITALIZATION.
por: Civettini, Ivan, et al.
Publicado: (2023)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

P1175: THROMBOTIC RISK IN DLBCL: A REAL-LIFE COMPARISON OF THE THROLY AND MODEL IX SCORES
por: Civettini, Ivan, et al.
Publicado: (2023)

P1056: NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES
por: Sangiorgio, Valentina, et al.
Publicado: (2023)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2013)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2014)

The Role of New Technologies in Myeloproliferative Neoplasms
por: Palumbo, Giuseppe A., et al.
Publicado: (2019)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review
por: Fontana, Diletta, et al.
Publicado: (2023)

Safety and Effectiveness of Intensive Treatments Administered Outside the Intensive Care Unit to Hematological Critically Ill Patients: An Intensive Care without Walls Trial
por: Vergnano, Beatrice, et al.
Publicado: (2023)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
por: Wan, Ziqi, et al.
Publicado: (2020)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

Tracking fibrosis in myeloproliferative neoplasms by CCR2 expression on CD34(+) cells
por: Pozzi, Giulia, et al.
Publicado: (2022)

Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies
por: Falcone, Rosa, et al.
Publicado: (2020)

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
por: Cominal, Juçara Gastaldi, et al.
Publicado: (2021)

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview
por: Kuendgen, Andrea, et al.
Publicado: (2021)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
por: Pettersson, Helna, et al.
Publicado: (2023)

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases
por: La Spina, Enrico, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Myeloproliferative neoplasms – blurring the lines between cancer and chronic inflammatory disorder
por: Soyfer, Eli M., et al.
Publicado: (2023)

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine
por: Fontana, Diletta, et al.
Publicado: (2020)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy
por: Li, Taotao, et al.
Publicado: (2022)

Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment
por: Symeonidis, Argiris, et al.
Publicado: (2023)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms
por: Moia, Riccardo, et al.
Publicado: (2021)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
por: Giannotta, Juri Alessandro, et al.
Publicado: (2021)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm
por: Kurian, Christine J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j4mnspcatujih4devdmfia9aaa